18 Nov 2022 - 20 Nov 2022
09:00 AM - 07:00 PM
6th Annual International Breast Cancer Conference
Program Director: Dr Sandeep Jasuja
6th Annual International Breast Cancer Conference - Hall B - 19 Nov 2022
Date : 19 Nov 2022
| Welcome & Introduction | 12:00 AM - 12:00 AM |
| Biomarker - based Targeted therapy for Colorectal Cancer | 12:00 AM - 12:00 AM |
| No Name | 12:00 AM - 12:00 AM |
| Novel Targeted agents in Gastric Cancer | 12:00 AM - 12:00 AM |
| PancreaticCancer Newertratement Options | 12:00 AM - 12:00 AM |
| Novel Agents and Targets in HCC | 12:00 AM - 12:00 AM |
| Update on Management of Advanced Biliary Tract cancer | 12:00 AM - 12:00 AM |
| Management of Metastic Hormon Prostate Cancer | 12:00 AM - 12:00 AM |
| Selection of RX for RCC-Adjuvant &1st Line Rx in Metastatic disease | 12:00 AM - 12:00 AM |
| 2nd Line options in Renal Cell Cancer | 12:00 AM - 12:00 AM |
| First-Line Immunotherapy in the management of RCC | 12:00 AM - 12:00 AM |
| Panel Discussion - Metastatic RCC | 12:00 AM - 12:00 AM |
| Current Treatment Landscape in first-line Urothelial Cancer | 12:00 AM - 12:00 AM |
| Overall survival at its core The New ABC Avelumab in Bladder Cancer | 12:00 AM - 12:00 AM |
| Panel Discussion- Management of Advance Bladder Cancer | 12:00 AM - 12:00 AM |
| Advances in Novel Formulation of Taxanes | 12:00 AM - 12:00 AM |
| Panel discussion - Management of Prostate cancer | 12:00 AM - 12:00 AM |
| Closing Remarks | 12:00 AM - 12:00 AM |
6th Annual International Breast Cancer Conference - 19 Nov 2022 - Hall A
Date : 19 Nov 2022
| Welcome & Introduction | 12:00 AM - 12:00 AM |
| Optimizing Treatment for First-line NSCLC | 12:00 AM - 12:00 AM |
| Personalized Therapy to Further Improve Outcomes in Patients with Braf Mutated mNSCLC | 12:00 AM - 12:00 AM |
| Evolving role of Immunotherapy in ES-SCLC | 12:00 AM - 12:00 AM |
| Panel Discussion - Achieving Dramatic Insights into Molecular Oncology & Precision Medicine of NSCLC MTB | 12:00 AM - 12:00 AM |
| Panel Discussion - Management of Early Lung Cancer | 12:00 AM - 12:00 AM |
| Real World Evidence Osimertinib as SoC ithe management of EGFRm NSCLC | 12:00 AM - 12:00 AM |
| Surgery After NACT in Locally Advanced Lung Cancer | 12:00 AM - 12:00 AM |
| Radiation in Locally Advanced Lung Cancer | 12:00 AM - 12:00 AM |
| Concurrent Chemotheprapy in Non-Small Cell Lung Cancer | 12:00 AM - 12:00 AM |
| Hidden EGFR Threats and Role of Amivantamab | 12:00 AM - 12:00 AM |
| Panel Discussion | 12:00 AM - 12:00 AM |
| Welcome | 12:00 AM - 12:00 AM |
| The importance of Thinking Holistically when caring for Head and Neck Patients | 12:00 AM - 12:00 AM |
| reviews | 12:00 AM - 12:00 AM |
| Osimertinib vs Dacomitinib | 12:00 AM - 12:00 AM |
| First line TKI+ something in EGFR mutated Lung Cancer | 12:00 AM - 12:00 AM |
| Osimertinib resistance mechanisms | 12:00 AM - 12:00 AM |
| Walk the first Line Management of Alk Positive NSCLC | 12:00 AM - 12:00 AM |
| Panel Discussion - Management of First-Line ALK-Rearranged NSCLC | 12:00 AM - 12:00 AM |
| Selection of 1st line therapy for MET amplification and MET Exon 14 mutation in NSCLC | 12:00 AM - 12:00 AM |
| Metastatic ROS I Positive Non Small Cell Lung Cancer | 12:00 AM - 12:00 AM |
| Panel Discussion - Management of Uncommon EGFR Mutations | 12:00 AM - 12:00 AM |
| Selection Of first Line Therapy for Exon 20 Insertion | 12:00 AM - 12:00 AM |
| Interpretation of PD1 MSI TMB in NSCLC | 12:00 AM - 12:00 AM |
| Slection of 1st line Immunotherapy in PDL1 Negative and non driver mutations-mNSCL-ca | 12:00 AM - 12:00 AM |
| Biomarkers for efficacy with immunotherapy | 12:00 AM - 12:00 AM |
| Closing Remarks | 12:00 AM - 12:00 AM |
6th Annual International Breast Cancer Conference - Hall B - 18 Nov 2022
Date : 18 Nov 2022
| Welcome & Introduction | 12:00 AM - 12:00 AM |
| Biomarkers in Head & Neck Cancer | 12:00 AM - 12:00 AM |
| Panel Discussion - Management of Locally Advanced Head & Neck Cancers | 12:00 AM - 12:00 AM |
| Nivolumab + ipilimumab vs EXTREME regimen as first line treatment for recurrent metastatic squamous cell carcinoma of the head and neck | 12:00 AM - 12:00 AM |
| A Phase II trial of Pembrolizumab and Cabozantinib in Patients with Recurent Metastatic Head and Neck Squamous Cell Carcinoma | 12:00 AM - 12:00 AM |
| A Phase II trial of Pembrolizumab and Cabozantinib in Patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma | 12:00 AM - 12:00 AM |
| Cetuximab docetaxel & cisplatin versus platinum fluorouracil & cetuximab as first line treatment in patients with recurrent or metastatic head & neck | 12:00 AM - 12:00 AM |
| Salvage surgery for Recurrent SCC Head & Neck | 12:00 AM - 12:00 AM |
| Panel Discussion - Management of Recurrent & metastatic Head & Neck Squamous Cell Carcinoma | 12:00 AM - 12:00 AM |
| Proton Therapy for Oral Cavity Cancers | 12:00 AM - 12:00 AM |
| Inaugural Function | 12:00 AM - 12:00 AM |
| Treatment Intensification in Locoregionally Advanced Head & Neck Squamous Cell Carcinoma | 12:00 AM - 12:00 AM |
| Approach to Salivary Gland tumors Role of anti Her2 therapy | 12:00 AM - 12:00 AM |
| Closing Remarks | 12:00 AM - 12:00 AM |
6th Annual International Breast Cancer Conference - Hall B - 20 Nov 2022
Date : 20 Nov 0222
| 6th Annual International Breast Cancer Conference Welcome & Introduction | 12:00 AM - 12:00 AM |
| Recent developments in advanced and recurrent Endometrial Cancer | 12:00 AM - 12:00 AM |
| Maintenance therapy in newly diagnosed ovarian Cancer | 12:00 AM - 12:00 AM |
| Molecular Classification of Endometrial Cancer and its Implications in Management | 12:00 AM - 12:00 AM |
| 6th Annual International Breast Cancer Conference Case Based Panel Discussion - Management of Advanced Ovarian Cancer | 12:00 AM - 12:00 AM |
| 6th Annual International Breast Cancer Conference Case Based Panel Discussion - Forming Oncofertility Team | 12:00 AM - 12:00 AM |
Program Director:
Dr Sandeep Jasuja
Contact Person
Garima Vashishtha
info@hcmpl.com
8178985238
Download